AstraZeneca rose 1.74% on the London Stock Exchange, to 7,350 pence per share, following information from the Sunday Telegraph that its anti-covid vaccine, co-developed with the University of Oxford, would be launched early January. The British newspaper said yesterday that it could be used as early as January 4, 2021 if the country’s health authorities give the green light this week. In the process, the Ministry of Health said that some time was still needed to study the data on this vaccine.
“The drug regulator is reviewing final data from the University of Oxford / AstraZeneca Phase 3 clinical trials to determine if the vaccine meets their strict standards for quality, safety and efficacy,” the ministry said. , Sunday.
According to some sources in the British press, a decision could in fact be taken as early as Tuesday. The Telegraph said authorization could be granted as early as next Sunday after AstraZeneca sent its latest data to the British Medicines Agency, the MHRA, on Monday evening.
The Telegraph also reveals that “mass vaccination centers in sports stadiums and conference venues are ready to be launched in the second week of January”, the government wishing to accelerate its vaccination program. Indeed, he wants two million people to receive their first dose of the vaccine, either from Oxford / AstraZeneca or from Pfizer / BioNTech, within fifteen days.
According to data released last Thursday, 600,000 people have received a dose of Pfizer / BioNTech’s vaccine in the UK. The country’s government has ordered 100 million from Oxford / AstraZeneca, of which 40 million are expected to be deployed by next March.
In an interview with yesterday Sunday TimesAstraZeneca CEO Pascal Soriot said his laboratory had found the “winning formula” for its vaccine and that it “should remain effective” against the new variant of covid-19.
source: AOF
■–